Zalcitabine FDA Link

A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by a hydrogen. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is a potent inhibitor of HIV replication at low concentrations, acting as a chain-terminator of viral DNA by binding to reverse transcriptase. Its principal toxic side effect is axonal degeneration resulting in peripheral neuropathy.

Also Known As:

Hivid; 2',3' Dideoxycytidine; HIVID Roche; NSC-606170; NSC 606170; NSC606170; 2',3'-Dideoxycytidine; Dideoxycytidine; ddC (Antiviral); Cytidine, 2',3'-dideoxy-

Pharmalogical Action Categories:

Anti-HIV Agents
Antimetabolites
Reverse Transcriptase Inhibitors

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Pyrimidines: 510
    - Pyrimidine Nucleosides: 50
      - Cytidine: 535
        Deoxycytidine: 307
        Zalcitabine: 278
Nucleic Acids, Nucleotides, and Nucleosides: 1
- Nucleosides: 6847
  - Pyrimidine Nucleosides: 50
    - Cytidine: 535
      - Deoxycytidine: 307
        Zalcitabine: 278
  - Deoxyribonucleosides: 34
    - Deoxycytidine: 307
      - Zalcitabine: 278
    - Dideoxynucleosides: 27
      - Zalcitabine: 278

3'-azido-2',3'-dideoxycytidine

Bio-Agent Context: Research Results